Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA

Expert Rev Vaccines. 2008 Feb;7(1):83-95. doi: 10.1586/14760584.7.1.83.

Abstract

In the year 2000, a heptavalent pneumococcal conjugate vaccine (PCV7) was licensed and recommended for routine immunization of infants in the USA. During the following years, a number of studies documented the impact of this immunization program on rates of invasive pneumococcal disease, pneumonia and otitis media. This article aims to summarize current evidence on the population-based impact of this infant immunization program in the USA.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Humans
  • Infant
  • Otitis Media / epidemiology
  • Otitis Media / prevention & control
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / administration & dosage*
  • Pneumonia / epidemiology
  • Pneumonia / prevention & control
  • United States / epidemiology

Substances

  • Pneumococcal Vaccines